U.S. markets open in 34 minutes
  • S&P Futures

    4,413.00
    -25.00 (-0.56%)
     
  • Dow Futures

    34,476.00
    -168.00 (-0.48%)
     
  • Nasdaq Futures

    15,187.50
    -116.00 (-0.76%)
     
  • Russell 2000 Futures

    2,240.40
    -14.80 (-0.66%)
     
  • Crude Oil

    73.19
    -0.11 (-0.15%)
     
  • Gold

    1,745.60
    -4.20 (-0.24%)
     
  • Silver

    22.44
    -0.23 (-1.03%)
     
  • EUR/USD

    1.1715
    -0.0032 (-0.27%)
     
  • 10-Yr Bond

    1.4250
    +0.0150 (+1.06%)
     
  • Vix

    20.32
    -0.55 (-2.64%)
     
  • GBP/USD

    1.3670
    -0.0050 (-0.37%)
     
  • USD/JPY

    110.5400
    +0.2390 (+0.22%)
     
  • BTC-USD

    41,206.80
    -2,346.52 (-5.39%)
     
  • CMC Crypto 200

    1,022.41
    -86.51 (-7.80%)
     
  • FTSE 100

    7,049.86
    -28.49 (-0.40%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. MiNK is a subsidiary of Agenus Inc. (NASDAQ: AGEN).

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com